Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study

作者全名："Chen, Zhulu; Zhang, Chuan; Zhu, Yuxi; Gao, Diansa; Mao, Min; Zuo, Zhong"

作者地址："[Chen, Zhulu; Zhang, Chuan; Gao, Diansa; Mao, Min; Zuo, Zhong] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China; [Zhu, Yuxi] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China"

通信作者："Zuo, Z (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China."

来源：MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001196708800022

JCR分区：Q2

影响因子：1.3

年份：2024

卷号：103

期号：12

开始页：　

结束页：　

文献类型：Article

关键词：cancer; heart failure; HFmrEF; HfpEF; HfrEF; Sacubitril/Valsartan

摘要："Sacubitril/Valsartan, the combination of angiotensin receptor inhibitor and neprilysin inhibitor, is now becoming the class 1 recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. By searching the patients with a diagnosis of both cancer and Heart failure (HF) over 65, the patients who had received treatment with Sacubitril/Valsartan were selected as the candidates for Sacubitril/Valsartan group, and the patients who had received conventional HF therapy without Sacubitril/Valsartan were chosen as the control group. Data were collected for up to 9 months. We filtered 38 patients and 50 patients valid for Sacubitril/Valsartan group and control group, respectively. After initiation of heart failure management, our study found a better cardiac condition in Sacubitril/Valsartan group, having better LVEF, LVFS, NT-proBNP in 3rd, 6th, 9th month (P < .05) and better NYHA function classification after the treatment. We also observed fewer cases of deterioration on LAD (P = .029) and LVEDD (P = .023) in Sacubitril/Valsartan group. In subgroup analysis, our study showed that all 3 kinds of HF patients had better LVEF, LVFS, and NT-proBNP in Sacubitril/Valsartan group (P < .05). Our study further indicated that Sacubitril/Valsartan can improve cardiac function and benefit cardiac remolding in aged cancer patients of all 3 kinds of HF. This is the first study to provide new evidence for the use of Sacubitril/Valsartan in aged cancer patients of 3 kinds of HF."

基金机构：Chongqing Medical Scientific Research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) [2023ZDXM011]; CQMU Program for Youth Innovation in Future Medicine [W0188]

基金资助正文：This work was supported by the Chongqing Medical Scientific Research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) (Grant No. 2023ZDXM011) and CQMU Program for Youth Innovation in Future Medicine (Grant No. W0188).